Research programme: neurodegenerative disorders therapeutics - Galantos Pharma

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Galantos Pharma

Alternative Names: Antidementia drugs programme - Galantos Pharma; Antidementive drugs programme - Galantos Pharma

Latest Information Update: 29 Nov 2012

Price : $50

At a glance

  • Originator Galantos Pharma
  • Class
  • Mechanism of Action Cholinergic receptor modulators; Cholinesterase inhibitors; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Neurodegenerative disorders

Most Recent Events

  • 15 May 2012 Discontinued - Preclinical for Alzheimer's disease in Germany (unspecified route)
  • 15 May 2012 Discontinued - Preclinical for Neurodegenerative disorders in Germany (unspecified route)
  • 29 Aug 2007 Galantos Pharma is seeking collaboration opportunities for this programme (http://www.galantos.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top